PSEN1 and Cognitive impairment: After data cleaning and quality control (QC; see Methods), we retained 67 samples and obtained molecular data for 16 carriers of pathogenic mutations in APP and PSEN1 (autosomal dominant AD; ADAD), 31 sAD non-carriers of risk-modifying variants, three individuals who matched AD-neuropathological criteria but without clinical cognitive impairment at age-of-death (presymptomatic), eight individuals who matched non-AD neurodegenerative pathologies criteria (other), and nine individuals who exhibited neither neurodegenerative pathology nor evidence of dementia (control) (Table 1).